Matauro LLC Invests $446,000 in Hims & Hers Health, Inc. $HIMS

Matauro LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,942 shares of the company’s stock, valued at approximately $446,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Northern Trust Corp boosted its holdings in Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd increased its stake in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after buying an additional 700,100 shares during the period. Nuveen LLC purchased a new stake in Hims & Hers Health during the 1st quarter worth approximately $58,403,000. BIT Capital GmbH increased its stake in Hims & Hers Health by 7.4% during the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after buying an additional 112,949 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Hims & Hers Health by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock worth $37,242,000 after buying an additional 15,339 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HIMS shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $38.92.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,622,727 shares of company stock valued at $83,566,691 over the last quarter. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $57.92 on Friday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a fifty-two week low of $16.05 and a fifty-two week high of $72.98. The firm has a market capitalization of $13.09 billion, a PE ratio of 72.40, a price-to-earnings-growth ratio of 3.80 and a beta of 2.25. The stock’s 50-day simple moving average is $51.57 and its 200-day simple moving average is $47.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the business posted $0.06 EPS. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.